Serum glycoproteins and immunoglobulins in nasopharyngeal carcinoma: correlations with Epstein-Barr virus associated antibodies and clinical tumor stage.

[1]  D. Byar,et al.  Response of serum haptoglobin to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer , 1978, Cancer.

[2]  P. K. Arora,et al.  α1-Antitrypsin is an effector of immunological stasis , 1978, Nature.

[3]  H. Coates,et al.  Epstein-Barr virus-associated antigens in nasopharyngeal carcinoma. , 1978, Archives of otolaryngology.

[4]  W. Henle,et al.  The immunological approach to study of possibly virus-induced human malignancies using the Epstein-Barr virus as example. , 1978, Progress in experimental tumor research.

[5]  A. Katz,et al.  Major Immunoglobulin Ratios in Carcinoma of the Head and Neck , 1978, The Annals of otology, rhinology, and laryngology.

[6]  H. Coates,et al.  Immunovirologic Assessment of American Patients with Nasopharyngeal Carcinoma and Occult Primary Tumors , 1978, Otolaryngology.

[7]  M. Ng,et al.  Immunohistochemistry of local immunoglobulin production in nasopharyngeal carcinoma. , 1978, British Journal of Cancer.

[8]  J. Ho.  An epidemiologic and clinical study of nasopharyngeal carcinoma. , 1978, International journal of radiation oncology, biology, physics.

[9]  H. Coates,et al.  An immunologic basis for detection of occult primary malignancies of the head and neck , 1978, Cancer.

[10]  Chrétien Pb,et al.  Immune reactivity in head and neck squamous carcinoma and relevance to the design of immunotherapy trials. , 1977 .

[11]  W. Henle,et al.  Nasopharyngeal carcinoma: Significance of changes in epstein‐barr virus‐related antibody patterns following therapy , 1977, International journal of cancer.

[12]  J. Weiss,et al.  Correlations among serum protein‐bound carbohydrates, serum glycoproteins, lymphocyte reactivity, and tumor burden in cancer patients , 1977, Cancer.

[13]  G. Klein,et al.  Relationship between the Epstein‐Barr virus and undifferentiated nasopharyngeal carcinoma: Correlated nucleic acid hybridization and histopathological examination , 1977, International journal of cancer.

[14]  C. Yang,et al.  Antibodies to Epstein-Barr virus capsid antigen and early antigen in nasopharyngeal carcinoma and comparison groups. , 1977, American journal of epidemiology.

[15]  Y. Nakajima,et al.  Antibody to Epstein-Barr virus in patients with carcinoma of the nasopharynx. , 1977, The Keio journal of medicine.

[16]  M. Hsu,et al.  Prognosis of nasopharyngeal carcinoma by Epstein-Barr virus antibody titer. , 1977, Archives of otolaryngology.

[17]  D. Henson,et al.  Viral-specific humoral immunity to herpes simplex-induced antigens in patients with squamous carcinoma of the head and neck. , 1976, American journal of surgery.

[18]  E. Lehmann,et al.  Nonparametrics: Statistical Methods Based on Ranks , 1976 .

[19]  W. Henle,et al.  Epstein‐barr virus‐specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma , 1976, International journal of cancer.

[20]  P. Chretien,et al.  Correlation of tumor burden with in vitro lymphocyte reactivity and antibodies to herpesvirus tumor‐associated antigens in head and neck squamous carcinoma , 1976, Cancer.

[21]  G. Klein.  The Epstein-Barr virus and neoplasia. , 1975, The New England journal of medicine.

[22]  N. Day,et al.  Nasopharyngeal carcinoma. IX. Antibodies to EBNA and correlation with response to other EBV antigens in Chinese patients , 1975, International journal of cancer.

[23]  T. Phillips,et al.  Elevated IgA in carcinoma of the nasopharynx , 1975, Cancer.

[24]  Y. Hinuma,et al.  Evaluation of epstein‐barr virus‐associated nuclear antigen with various human cell lines , 1974, International journal of cancer.

[25]  W. Henle,et al.  Demonstration of epstein‐barr virus‐associated nuclear antigen in nasopharyngeal carcinoma cells from fresh biopsies , 1974, International journal of cancer.

[26]  C. Alper.  Plasma protein measurements as a diagnostic aid. , 1974, The New England journal of medicine.

[27]  W. Henle,et al.  False negative and prozone reactions in tests for antibodies to Epstein‐Barr virus‐associated nuclear antigen , 1974, International journal of cancer.

[28]  B. Henderson.  Nasopharyngeal carcinoma: present status of knowledge. , 1974, Cancer research.

[29]  G. Klein,et al.  EB virus‐associated antibodies in caucasian patients with carcinoma OE the nasopharynx and in long‐term survivors after treatment , 1974, International journal of cancer.

[30]  B. Mccabe,et al.  Anti-Epstein Barr Virus Antibody in Nasopharyngeal Carcinoma , 1974, The Annals of otology, rhinology, and laryngology.

[31]  J. Chiou,et al.  Further studies on antibodies to early antigens induced by Epstein-Barr virus in nasopharyngeal carcinoma patients. , 1973, Gan.

[32]  C. Yang,et al.  Seroepidemiological studies on carcinoma of the nasopharynx. , 1973, Cancer research.

[33]  J. Fleiss,et al.  Statistical methods for rates and proportions , 1973 .

[34]  W. Henle,et al.  Antibodies to Epstein-Barr virus-related antigens in nasopharyngeal carcinoma. Comparison of active cases with long-term survivors. , 1973, Journal of the National Cancer Institute.

[35]  G. Klein,et al.  Cellular localization of an Epstein‐Barr virus (EBV)‐associated complement‐fixing antigen in producer and non‐producer lymphoblastoid cell lines , 1973, International journal of cancer.

[36]  T. Hirayama,et al.  Nasopharyngeal carcinoma and Epstein-Barr virus. I. Factors related to the anti-VCA antibody. , 1973, The Japanese journal of experimental medicine.

[37]  T. Hirayama,et al.  Nasopharyngeal carcinoma and Epstein-Barr virus. II. Clinical course and the anti-VCA antibody. , 1973, The Japanese journal of experimental medicine.

[38]  S. Nagase.  Glycoproteins in relation to cancer , 1972 .

[39]  A. Strinchini,et al.  B.C.N.U. (1,3-bis (2-chloroethyl) -1-nitrosourea) in the treatment of advanced Hodgkin's disease. , 1972, Lancet.

[40]  C. Yang,et al.  Antibodies to herpes‐type virus in nasopharyngeal carcinoma and control groups , 1972, Cancer.

[41]  G. Ashwell,et al.  Quantitation of specific serum glycoproteins in malignancy. , 1971, Clinica chimica acta; international journal of clinical chemistry.

[42]  W. K. Mueller,et al.  Serum Haptoglobin in Patients with Ovarian Malignancies , 1971, Obstetrics and gynecology.

[43]  H. Sjögren,et al.  Blocking of cell‐mediated tumor immunity by sera from patients with growing neoplasms , 1971, International journal of cancer.

[44]  F. Jansen,et al.  BIOLOGICAL PROPERTIES OF ANTIBODY CLASSES IN TRANSPLANTATION IMMUNE SERA , 1969, Transplantation.

[45]  J. Heremans,et al.  Immunochemical quantitation of antigens by single radial immunodiffusion. , 1965, Immunochemistry.

[46]  J. H. Pope.  The biology of EB virus , 1978 .

[47]  Yeu‐Tsu N. Lee,et al.  Quantitative change of serum protein and immunoglobulin in patients with solid cancers , 1977, Journal of surgical oncology.

[48]  M. Romsdahl,et al.  IgA as a blocking factor in human malignant melanoma. , 1974, Immunological communications.

[49]  V. Diehl,et al.  Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. , 1970, Journal of the National Cancer Institute.